Silver Book Fact

From 1975 to 1996, new cancer drugs increased life expectancy of cancer patients by about one year, at an estimated cost of $3,000—well below the estimated value of a statistical life-year.

The Expanding Pharmaceutical Arsenal in the War on Cancer. NBER Working Paper Series Web site. http://www.nber.org/papers/w10328. Published 2004

Reference

Title
The Expanding Pharmaceutical Arsenal in the War on Cancer
Publication
NBER Working Paper Series
Publication Date
Published 2004
Authors
Lichtenberg, F
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Reductions in mortality for lung, female breast, prostate, and colorectal cancers accounted for 60 to 80 percent of the total decrease in all cancer deaths since the early 1990s.  
  • Use of a monocolonal antibody with adjuvant chemotherapy in HER2+ individuals with operable cancer was associated with a 33 percent reduction in risk of death.  
  • 5-Year Relative Survival Rates for Cancers in U.S.  
  • The 5-year survival rate for prostate cancer has increased from 67% to nearly 100% over the past 20 years.  
  • The 5-year survival rate for all cancers diagnosed from 1996-2003 is 66%, up from 50% in 1975-1977. This improvement reflects progress in early diagnosis and improvements in treatment.